Filing Flows › Health Care › electroCore (ECOR)
electroCore (ECOR) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · electroCore (ECOR) Q3 2026 earnings results →
Q3 2026 Revenue up 12% year over year to $9.7M · 14¢ of every $1 of revenue lost · operating margin -16.1%
electroCore made $9.7M in Q3 2026 (+12% Y/Y). Operating margin -16.1%, net loss $1.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $9.7M in Q3 2026, up 12% year over year and up 3% from the previous quarter.
Gross margin was 88.5%, up 2.5 points from Q3 2025. Operating costs exceeded revenue by $1.6M, an operating margin of -16.1%. Operating expenses fell 2% while revenue rose 12%. The quarter ended with a net loss of $1.3M, narrower than the previous quarter's $3.1M loss.
Operating cash flow was −$2.8M. Non-cash charges added back $9K of depreciation and amortization and $617K of share-based compensation. Working capital and other items used $2.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $9.7M | +12% | -16.1% | −$1.3M | −$2.8M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $9.4M | +28% | -29.3% | −$3.1M | −$3.5M |
| Q1 2026 | 10-Q | May 6, 2026 | $9.6M | +43% | -55.5% | −$5.3M | −$3.0M |
| Q4 2025 | 10-K | Mar 19, 2026 | $9.2M | +31% | -31.8% | −$3.0M | −$1.5M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $8.7M | +33% | -33.2% | −$3.4M | −$1.7M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $7.4M | +20% | -47.5% | −$3.7M | −$623K |
| Q1 2025 | 10-Q | May 7, 2025 | $6.7M | +23% | -56.9% | −$3.9M | −$4.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About electroCore
ElectroCore is a bioelectronic medicine and general wellness company dedicated to improving health and quality of life through our proprietary non-invasive vagus nerve stimulation (“nVNS”) technology platform and related product offerings . nVNS modulates neurotransmitters through its effects on both the peripheral and central nervous systems. Our nVNS treatment is delivered through a proprietary high-frequency burst waveform that safely and comfortably passes through the skin and stimulates therapeutically relevant fibers in the vagus nerve. Various scientific publications suggest that nVNS works through a variety of mechanistic pathways including the modulation of neurotransmitters.
In its own words, from its 10-K, filed Mar 12, 2025.
electroCore against its Electromedical & Electrotherapeutic Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +12% against the peers' median +14%. Operating margin: -16.1% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ECOR electroCore | Q3 2026 | $9.7M | +12% | -16.1% |
| MDT Medtronic | Q1 FY27 | $9.8B | +14% | 18.1% |
| ITGR Integer Holdings | Q3 2026 | $450M | -4% | 6.3% |
| LIVN LivaNova | Q3 2026 | $393M | +10% | 7.2% |
| CNMD Conmed | Q3 2026 | $336M | -0.7% | 11.1% |
| TMDX TransMedics Group | Q3 2026 | $203M | +41% | 13.9% |
| AXGN Axogen | Q3 2026 | $75.8M | +26% | 1.3% |
| OM Outset Medical | Q3 2026 | $33.6M | +14% | -36.5% |
| CBLL Ceribell | Q3 2026 | $29.3M | +30% | -70.0% |
Source: electroCore 10-Q on SEC EDGAR · CIK 1560258 · Electromedical & Electrotherapeutic Apparatus
Guidance and outlook
13F: who owns ECOR and who is buying
More on ECOR
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results